Table 2.
Clinical and laboratory characteristics of the study population.
| Mild/moderate patients | Severe/critical patients | P-values | |
|---|---|---|---|
| Age (years) | 42.91 ± 1.881 | 41.28 ± 1.549 | 0.5073 |
| Gender (female/male) | 10/22 | 8/24 | 0.7816 |
| WBC (×109) | 14.09 ± 2.190 | 17.59 ± 1.418 | 0.1842 |
| MONO % | 10.97 ± 0.5358 | 9.739 ± 0.8122 | 0.2094 |
| Heteromorphic Lymphocytes % lymphocytes % | 9.539 ± 0.8992 | 10.54 ± 0.8366 | 0.4186 |
| PLT (×109) | 106.0 ± 7.198 | 81.16 ± 6.535 | 0.0132* |
| BUN, mmol/l | 10.34 ± 0.9818 | 22.27 ± 1.340 | <0.0001** |
| Scr, μmol/l | 206.6 ± 22.84 | 302.6 ± 26.01 | 0.0073** |
WBC, White blood cells; PLT, platelets; MONO %, monocyte percentage; BUN, blood urea nitrogen; Scr, serum creatinine. Values are presented as the mean ± SEM. P-value refers to the difference between mild and severe patients calculated using an unpaired t-test, except for the factor age (Fisher's exact test).
*
P < 0.05,
**
P < 0.01 compared with the mild patients.